Meeting
2016 ASCO Annual Meeting
Influence of KRAS exon 2 mutation variants as well as NRAS- and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab.
Authors
Dominik Paul Modest
Department of Hematology and Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany
Dominik Paul Modest , Ingrid Ricard , Volker Heinemann , Susanna Hegewisch-Becker , Wolff H. Schmiegel , Rainer Porschen , Sebastian Stintzing , Ullrich Graeven , Dirk Arnold , Ludwig Fischer Von Weikersthal , Clemens Giessen-Jung , Arndt Stahler , Hans-Joachim Schmoll , Andreas Jung , Thomas Kirchner , Andrea Tannapfel , Anke C. Reinacher-Schick
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3551)
DOI
10.1200/JCO.2016.34.15_suppl.3551
Abstract #
3551
Poster Bd #
248
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.
First Author: Jonathan M. Loree
Poster
2016 ASCO Annual Meeting
Association of right-sided colon cancer with poor efficacy of cetuximab in patients with RAS wild-type metastatic colorectal cancer.
First Author: Dalyong Kim
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real world effectiveness of regorafenib in heavily pretreated patients with metastatic colorectal cancer.
First Author: Anastasia Danilova
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Mutation status of full RAS and BRAF in 169 Moroccan patients with colorectal cancer.
First Author: Sara El Zaitouni